trastuzumab SC (EG13074) / EirGenix - LARVOL DELTA

Efficacy and Safety of EG12014 (Biosimilar Trastuzumab) Compared to Reference Trastuzumab in HER2-Positive Early Breast Cancer: A Phase III Randomized Study. (PubMed, Adv Ther) - P3 | "Trastuzumab biosimilar EG12014 and ref-TRA have equivalent efficacy, and comparable safety, immunogenicity, and PK profiles, in patients with EBC. Clinical trial registration NCT03433313; EudraCT Number 2017-003973-33."

Journal • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

EGC102: Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer. (clinicaltrials.gov) - P3 | N=0 | Withdrawn | Sponsor: EirGenix, Inc. | N=380 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor

EGC102: Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared with EU-sourced Perjeta® (Pertuzumab) in Patients with HER2-positive Hormone Receptor Negative Early Breast Cancer. (clinicaltrials.gov) - P3 | N=380 | Not yet recruiting | Sponsor: EirGenix, Inc.

New P3 trial • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor